Dr Reddy's Laboratories had received the manufacturing licence for semaglutide in December 2024 and it began production in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...

Men arrested by College of Charleston police for having guns on campus June 1 will not face immediate charges due to their ...

Dr. Reddy’s and OneSource agree not to sell Novo Nordisk’s anti-obesity drug in India amid patent infringement lawsuit.

Join ITR and Thomson Reuters on June 25 as a three-part webinar series concludes with real-world insights into how businesses ...

Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

Further, the name of the Company has been changed from Stelis Biopharma Limited to OneSource Specialty Pharma Limited effective February 13, 2024. The Company did not make any profits during the ...

Dallas dropped the first of back-to-back games against Chicago, and the Wings will be without top pick Paige Buckers in the second game.

The Delhi High Court has restrained Dr. Reddy’s Laboratories and OneSource Specialty Pharma from selling or marketing of diabetes and anti-obesity drug semaglutide, sold by Danish drugmaker Novo ...

Onesource Industries And Venture shareholdings: Gain valuable insights into Onesource Industries And Venture shareholdings and ownership. Explore the shareholding pattern and information on ...